Healios K.K. (4593.T)
JPY 323.0
(0.94%)
JPY 323.0
(0.94%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -3.82 Billion JPY | 26.05% |
| 2022 | -5.17 Billion JPY | -5.25% |
| 2021 | -4.91 Billion JPY | 10.9% |
| 2020 | -5.51 Billion JPY | -25.04% |
| 2019 | -4.4 Billion JPY | 13.5% |
| 2018 | -5.09 Billion JPY | -186.89% |
| 2017 | -1.77 Billion JPY | 48.26% |
| 2016 | -3.43 Billion JPY | -258.37% |
| 2015 | -958.1 Million JPY | -100.75% |
| 2014 | -477.25 Million JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -534 Million JPY | 77.98% |
| 2024 Q1 | -2.42 Billion JPY | -40.09% |
| 2023 Q4 | -1.73 Billion JPY | -147.29% |
| 2023 FY | -3.82 Billion JPY | 26.05% |
| 2023 Q2 | -660 Million JPY | 9.47% |
| 2023 Q1 | -729 Million JPY | 39.9% |
| 2023 Q3 | -700 Million JPY | -6.06% |
| 2022 Q1 | -1.46 Billion JPY | -20.15% |
| 2022 Q4 | -1.21 Billion JPY | -74.03% |
| 2022 FY | -5.17 Billion JPY | -5.25% |
| 2022 Q3 | -697 Million JPY | 61.28% |
| 2022 Q2 | -1.8 Billion JPY | -23.2% |
| 2021 Q3 | -1.8 Billion JPY | -108.92% |
| 2021 FY | -4.91 Billion JPY | 10.9% |
| 2021 Q1 | -1.02 Billion JPY | 31.31% |
| 2021 Q2 | -863 Million JPY | 16.13% |
| 2021 Q4 | -1.21 Billion JPY | 32.56% |
| 2020 FY | -5.51 Billion JPY | -25.04% |
| 2020 Q4 | -1.49 Billion JPY | -6.62% |
| 2020 Q3 | -1.4 Billion JPY | -4.46% |
| 2020 Q2 | -1.34 Billion JPY | -6.49% |
| 2020 Q1 | -1.26 Billion JPY | 0.16% |
| 2019 FY | -4.4 Billion JPY | 13.5% |
| 2019 Q2 | -1.03 Billion JPY | -15.4% |
| 2019 Q1 | -896 Million JPY | 13.76% |
| 2019 Q3 | -1.01 Billion JPY | 1.93% |
| 2019 Q4 | -1.26 Billion JPY | -24.75% |
| 2018 Q4 | -1.03 Billion JPY | -41.36% |
| 2018 FY | -5.09 Billion JPY | -186.89% |
| 2018 Q2 | -2.77 Billion JPY | -400.9% |
| 2018 Q1 | -553 Million JPY | 2.52% |
| 2018 Q3 | -735 Million JPY | 73.47% |
| 2017 Q1 | -526.42 Million JPY | -59.51% |
| 2017 Q4 | -567.27 Million JPY | 34.54% |
| 2017 Q2 | 183.7 Million JPY | 134.9% |
| 2017 Q3 | -866.65 Million JPY | -571.77% |
| 2017 FY | -1.77 Billion JPY | 48.26% |
| 2016 Q1 | -2.13 Billion JPY | -466.82% |
| 2016 FY | -3.43 Billion JPY | -258.37% |
| 2016 Q4 | -330.03 Million JPY | 27.22% |
| 2016 Q3 | -453.49 Million JPY | 12.51% |
| 2016 Q2 | -518.35 Million JPY | 75.68% |
| 2015 Q4 | -376.07 Million JPY | -128.88% |
| 2015 Q1 | -241.78 Million JPY | 0.0% |
| 2015 Q2 | -175.93 Million JPY | 27.23% |
| 2015 Q3 | -164.3 Million JPY | 6.61% |
| 2015 FY | -958.1 Million JPY | -100.75% |
| 2014 FY | -477.25 Million JPY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 384 Million JPY | 1095.573% |
| PRISM BioLab Co.,LTD | -526.91 Million JPY | -625.545% |
| GNI Group Ltd. | 8.09 Billion JPY | 147.231% |
| Linical Co., Ltd. | 338.26 Million JPY | 1230.176% |
| Trans Genic Inc. | 4.08 Million JPY | 93686.291% |
| MEDINET Co., Ltd. | -1.43 Billion JPY | -165.865% |
| Soiken Holdings Inc. | -662.2 Million JPY | -477.315% |
| Cytori Cell Research Institute, Inc. | 138.15 Million JPY | 2867.182% |
| AnGes, Inc. | -7.43 Billion JPY | 48.599% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | -196.785% |
| Nxera Pharma Co., Ltd. | -7.19 Billion JPY | 46.851% |
| Immuno-Biological Laboratories Co., Ltd. | 186.69 Million JPY | 2147.736% |
| NanoCarrier Co., Ltd. | -780 Million JPY | -390.127% |
| Carna Biosciences, Inc. | -1.15 Billion JPY | -231.6% |
| CanBas Co., Ltd. | -1.2 Billion JPY | -216.212% |
| D. Western Therapeutics Institute, Inc. | -812.41 Million JPY | -370.575% |
| RaQualia Pharma Inc. | -323.66 Million JPY | -1081.17% |
| Chiome Bioscience Inc. | -1.22 Billion JPY | -213.356% |
| Kidswell Bio Corporation | -1.42 Billion JPY | -168.832% |
| PeptiDream Inc. | 3.03 Billion JPY | 225.929% |
| Oncolys BioPharma Inc. | -1.93 Billion JPY | -97.214% |
| Ribomic Inc. | -1.02 Billion JPY | -273.253% |
| SanBio Company Limited | -2.64 Billion JPY | -44.592% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | -227.289% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.48 Billion JPY | -156.646% |
| Delta-Fly Pharma, Inc. | -1.42 Billion JPY | -167.456% |
| StemRIM | -2.02 Billion JPY | -89.07% |
| CellSource Co., Ltd. | 923.14 Million JPY | 514.129% |
| FunPep Company Limited | -933.41 Million JPY | -309.571% |
| Kringle Pharma, Inc. | -854.15 Million JPY | -347.579% |
| Stella Pharma Corporation | -763.74 Million JPY | -400.557% |
| TMS Co., Ltd. | -960.04 Million JPY | -298.213% |
| Noile-Immune Biotech Inc. | -1.13 Billion JPY | -238.314% |
| Cuorips Inc. | -632.18 Million JPY | -504.73% |
| K Pharma,Inc. | 260.33 Million JPY | 1568.521% |
| Takara Bio Inc. | 1.48 Billion JPY | 358.311% |
| ReproCELL Incorporated | -31.41 Million JPY | -12069.346% |
| PhoenixBio Co., Ltd. | 26.37 Million JPY | 14593.138% |
| StemCell Institute Inc. | 310.98 Million JPY | 1329.336% |
| Japan Tissue Engineering Co., Ltd. | 143.16 Million JPY | 2770.271% |
| CellSeed Inc. | -846.53 Million JPY | -351.606% |